Akebia Therapeutics Inc (AKBA) concluded trading on Thursday at a closing price of $3.01, with 7.55 million shares of worth about $22.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 60.11% during that period and on May 29, 2025 the price saw a gain of about 4.51%. Currently the company’s common shares owned by public are about 261.64M shares, out of which, 251.86M shares are available for trading.
Stock saw a price change of 7.12% in past 5 days and over the past one month there was a price change of 23.87%. Year-to-date (YTD), AKBA shares are showing a performance of 58.42% which increased to 173.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.80 but also hit the highest price of $2.97 during that period. The average intraday trading volume for Akebia Therapeutics Inc shares is 4.82 million. The stock is currently trading 14.30% above its 20-day simple moving average (SMA20), while that difference is up 32.99% for SMA50 and it goes to 59.44% higher than SMA200.
Akebia Therapeutics Inc (NASDAQ: AKBA) currently have 261.64M outstanding shares and institutions hold larger chunk of about 36.60% of that.
The stock has a current market capitalization of $790.53M and its 3Y-monthly beta is at 0.82. It has posted earnings per share of -$0.22 in the same period. It has Quick Ratio of 2.02 while making debt-to-equity ratio of 8.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKBA, volatility over the week remained 2.40% while standing at 3.58% over the month.
Analysts are in expectations that Akebia Therapeutics Inc (AKBA) stock would likely to be making an EPS of -0.04 in the current quarter, while forecast for next quarter EPS is -0.03 and it is 0.42 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.04 which is -0.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.04 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 68.48% while it is estimated to increase by 117.31% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on April 28, 2025 offering an Outperform rating for the stock and assigned a target price of $7 to it. Coverage by Jefferies stated Akebia Therapeutics Inc (AKBA) stock as a Buy in their note to investors on April 01, 2025, suggesting a price target of $6 for the stock. On November 29, 2023, BTIG Research Resumed their recommendations, while on August 28, 2023, H.C. Wainwright Upgrade their ratings for the stock with a price target of $3.75. Stock get an Overweight rating from Piper Sandler on May 31, 2023.
